Anti-receptor and growth blocking antibodies to the vitamin B.sub.12 /transcobalamin II receptor and binding sites
AssigneeReceptagen Corporation
InventorAlton Charles Morgan, Jr.
Life of this patent
Estimating the term…
Abstract
There is disclosed anti-receptor and growth blocking agents to the vitamin B.sub.12 /transcobalamin II receptor and binding sites. The anti-receptor and growth blocking agents antagonize or modulate the vitamin B.sub.12 /transcobalamin II receptor or binding sites, causing cellular depletion of vitamin B.sub.12, thus preventing or inhibiting cell division or causing apoptosis. Anti-receptor and growth blocking agents of the present invention include proteins (such as antibodies and antibody derivatives), peptides and small organic molecules. In a preferred embodiment, the anti-receptor agent is an antibody to the vitamin B.sub.12 /transcobalamin II receptor.
Claims21
A method for inhibiting cell division of a target cell in a warm-blooded animal, comprising administering to the animal a monoclonal anti-receptor antibody to a vitamin B.sub.12 /transcobalamin II receptor on the surface of the target cell, said monoclonal antibody being capable of competitively antagonizing or modulating the receptor to prevent or inhibit cellular uptake of vitamin B.sub.12 by the target cell.
A method for preventing or inhibiting cellular uptake of vitamin B.sub.12 in a warm-blooded animal, comprising administering to the animal monoclonal anti-receptor antibody to a vitamin B.sub.12 /transcobalamin II receptor on the surface of the cell, said monoclonal antibody being capable of competitively antagonizing or modulating the receptor to prevent or inhibit the cellular uptake of vitamin B.sub.12.
A method of inhibiting cell division in a warm blooded animal comprising administering to a warm blooded animal a therapeutically effective amount of a monoclonal anti-receptor antibody to a vitamin B.sub.12 /transcobalamin II receptor on the surface of the cell, said monoclonal antibody being capable of competitively antagonizing or modulating the binding site to prevent or inhibit the uptake of vitamin B.sub.12 by TcII.
A method of preventing or inhibiting cellular uptake of vitamin B.sub.12, comprising administering to an animal a therapeutically effective mount of a monoclonal anti-receptor antibody to a vitamin B.sub.12 /transcobalamin II receptor on the surface of the cell, said monoclonal antibody being capable of competitively antagonizing or modulating the binding site to prevent or inhibit the uptake of vitamin B.sub.12 by TcII.
A method of preventing or inhibiting cellular uptake of vitamin B.sub.12, comprising administering to a biological preparation an effective amount of a monoclonal anti-receptor antibody to a vitamin B.sub.12 /transcobalamin II receptor on the surface of the cell, said monoclonal antibody being capable of competitively antagonizing or modulating the binding site to prevent or inhibit the uptake of vitamin B.sub.12 by TcII.
A method of inhibiting cell division in a warm blooded animal comprising administering to a warm blooded animal a therapeutically effective amount of a monoclonal antibody to a binding site on a TcII/B.sub.12 complex, said monoclonal antibody being capable of competitively antagonizing or modulating said binding site to prevent or inhibit the binding of said TcII/B.sub.12 complex to the cell surface.
A method of preventing or inhibiting cellular uptake of vitamin B.sub.12 comprising administering to an animal an effective amount of a monoclonal antibody to a binding site on a TcII/B.sub.12 complex, said monoclonal antibody being capable of competitively antagonizing or modulating said binding site to prevent or inhibit the binding of said TcII/B.sub.12 complex to the cell surface.
A method of inhibiting cellular uptake of vitamin B.sub.12 comprising administering to a biological preparation an effective amount of a monoclonal antibody to a binding site on a TcII/B.sub.12 complex, said monoclonal antibody being capable of competitively antagonizing or modulating said binding site to prevent or inhibit the binding of said TcII/B.sub.12 complex to the cell surface.
Dependencies are inferred from the claim text.